{"entity":{"id":"swog","kind":"company","name":"SWOG Cancer Research Network","aka":["SWOG","Southwest Oncology Group"],"tldr":"SWOG is one of the US National Cancer Institute's cooperative groups: thousands of community and academic sites running practice-changing trials, including the 2026 first-line Hodgkin lymphoma result.","summary":"Founded 1956 (Southwest Oncology Group). NCI National Clinical Trials Network member with >12,000 members at >1,300 sites. Landmark trials include S1826 (nivolumab-AVD in advanced Hodgkin lymphoma, FDA approval March 2026), S1418/BR006 (adjuvant pembrolizumab in TNBC), and the de-escalation trial SCARLET (S2212) in stage II-III TNBC. Statistical centre at Fred Hutchinson Cancer Center.","asOf":"2026-09-06","links":[{"label":"Official website","url":"https://www.swog.org"}],"tags":["cooperative-group"],"related":["nivolumab"],"cancers":["hodgkin-lymphoma","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["fred-hutch","nci"],"pathways":[],"terms":[],"trials":["scarlet-s2212","int-0116"],"people":["kathy-albain","anne-chiang","hagen-kennecke","charles-blanke","dawn-hershman","neeraj-agarwal","primo-lara","priyanka-sharma"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["NCTN cooperative group","S1826 Hodgkin lymphoma","SCARLET S2212 (TNBC de-escalation)","Cancer control and survivorship"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Portland, OR","country":"US","companyType":"cooperative-group","website":"https://www.swog.org","founded":1956,"investors":[],"funding":[]},"route":"/companies/swog/","neighbours":{"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"institution":[{"id":"fred-hutch","kind":"institution","name":"Fred Hutchinson Cancer Center","route":"/institutions/fred-hutch/"},{"id":"columbia-hicc","kind":"institution","name":"Herbert Irving Comprehensive Cancer Center, Columbia University","route":"/institutions/columbia-hicc/"},{"id":"huntsman","kind":"institution","name":"Huntsman Cancer Institute, University of Utah","route":"/institutions/huntsman/"},{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"},{"id":"ohsu-knight","kind":"institution","name":"OHSU Knight Cancer Institute","route":"/institutions/ohsu-knight/"},{"id":"ku-cancer-center","kind":"institution","name":"The University of Kansas Cancer Center","route":"/institutions/ku-cancer-center/"},{"id":"uc-davis-cancer","kind":"institution","name":"UC Davis Comprehensive Cancer Center","route":"/institutions/uc-davis-cancer/"},{"id":"usc-norris","kind":"institution","name":"USC Norris Comprehensive Cancer Center","route":"/institutions/usc-norris/"},{"id":"emory-winship","kind":"institution","name":"Winship Cancer Institute of Emory University","route":"/institutions/emory-winship/"}],"trial":[{"id":"nct07802626","kind":"trial","name":"Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing","route":"/trials/nct07802626/"},{"id":"alchemist","kind":"trial","name":"ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)","route":"/trials/alchemist/"},{"id":"calgb-80405","kind":"trial","name":"CALGB/SWOG 80405","route":"/trials/calgb-80405/"},{"id":"dart-s1609","kind":"trial","name":"DART (SWOG S1609): nivolumab plus ipilimumab in rare tumours","route":"/trials/dart-s1609/"},{"id":"drammatic","kind":"trial","name":"DRAMMATIC","route":"/trials/drammatic/"},{"id":"nct07018869","kind":"trial","name":"Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors","route":"/trials/nct07018869/"},{"id":"int-0116","kind":"trial","name":"INT-0116 (Macdonald trial)","route":"/trials/int-0116/"},{"id":"nct06807437","kind":"trial","name":"Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula","route":"/trials/nct06807437/"},{"id":"lung-map","kind":"trial","name":"Lung-MAP (SWOG S1400 and S1900)","route":"/trials/lung-map/"},{"id":"lung-map-s1400i","kind":"trial","name":"Lung-MAP S1400I: nivolumab with or without ipilimumab","route":"/trials/lung-map-s1400i/"},{"id":"lung-map-s1800a","kind":"trial","name":"Lung-MAP S1800A: ramucirumab plus pembrolizumab","route":"/trials/lung-map-s1800a/"},{"id":"rxponder","kind":"trial","name":"RxPONDER (SWOG S1007)","route":"/trials/rxponder/"},{"id":"nct01349881","kind":"trial","name":"S0820, Adenoma and Second Primary Prevention Trial","route":"/trials/nct01349881/"},{"id":"nct04155034","kind":"trial","name":"S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cel","route":"/trials/nct04155034/"},{"id":"scarlet-s2212","kind":"trial","name":"SCARLET (SWOG S2212)","route":"/trials/scarlet-s2212/"},{"id":"nct03678025","kind":"trial","name":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","route":"/trials/nct03678025/"},{"id":"nct06998940","kind":"trial","name":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","route":"/trials/nct06998940/"},{"id":"swog-8794","kind":"trial","name":"SWOG 8794","route":"/trials/swog-8794/"},{"id":"swog-9346","kind":"trial","name":"SWOG 9346 (intermittent androgen deprivation)","route":"/trials/swog-9346/"},{"id":"swog-9916","kind":"trial","name":"SWOG 9916","route":"/trials/swog-9916/"},{"id":"swog-s0421-atrasentan","kind":"trial","name":"SWOG S0421","route":"/trials/swog-s0421-atrasentan/"},{"id":"swog-s0809","kind":"trial","name":"SWOG S0809","route":"/trials/swog-s0809/"},{"id":"swog-s1406","kind":"trial","name":"SWOG S1406","route":"/trials/swog-s1406/"},{"id":"swog-s1418","kind":"trial","name":"SWOG S1418 / NRG BR006","route":"/trials/swog-s1418/"},{"id":"swog-s1505","kind":"trial","name":"SWOG S1505","route":"/trials/swog-s1505/"},{"id":"swog-s1801","kind":"trial","name":"SWOG S1801","route":"/trials/swog-s1801/"},{"id":"swog-s1815","kind":"trial","name":"SWOG S1815","route":"/trials/swog-s1815/"},{"id":"swog-s1826","kind":"trial","name":"SWOG S1826","route":"/trials/swog-s1826/"},{"id":"nct05096663","kind":"trial","name":"Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer","route":"/trials/nct05096663/"}],"person":[{"id":"alex-herrera","kind":"person","name":"Alex F. Herrera","route":"/people/alex-herrera/"},{"id":"anne-chiang","kind":"person","name":"Anne C. Chiang","route":"/people/anne-chiang/"},{"id":"charles-blanke","kind":"person","name":"Charles D. Blanke","route":"/people/charles-blanke/"},{"id":"dawn-hershman","kind":"person","name":"Dawn L. Hershman","route":"/people/dawn-hershman/"},{"id":"hagen-kennecke","kind":"person","name":"Hagen F. Kennecke","route":"/people/hagen-kennecke/"},{"id":"kathy-albain","kind":"person","name":"Kathy S. Albain","route":"/people/kathy-albain/"},{"id":"mariana-chavez-macgregor","kind":"person","name":"Mariana Chavez-MacGregor","route":"/people/mariana-chavez-macgregor/"},{"id":"michael-leblanc","kind":"person","name":"Michael LeBlanc","route":"/people/michael-leblanc/"},{"id":"neeraj-agarwal","kind":"person","name":"Neeraj Agarwal","route":"/people/neeraj-agarwal/"},{"id":"primo-lara","kind":"person","name":"Primo N. Lara Jr.","route":"/people/primo-lara/"},{"id":"priyanka-sharma","kind":"person","name":"Priyanka Sharma","route":"/people/priyanka-sharma/"},{"id":"virginia-sun","kind":"person","name":"Virginia Sun","route":"/people/virginia-sun/"}],"paper":[{"id":"paper-venook-calgb-80405-cetuximab-vs-bevacizumab-jama-2017","kind":"paper","name":"Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in KRAS wild-type advanced or metastatic colorectal cancer (CALGB/SWOG 80405)","route":"/key-papers/paper-venook-calgb-80405-cetuximab-vs-bevacizumab-jama-2017/"},{"id":"paper-swog-s0809-adjuvant-chemoradiation-jco-2015","kind":"paper","name":"SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma","route":"/key-papers/paper-swog-s0809-adjuvant-chemoradiation-jco-2015/"},{"id":"paper-swog-s1826-nivolumab-avd-nejm-2024","kind":"paper","name":"SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults","route":"/key-papers/paper-swog-s1826-nivolumab-avd-nejm-2024/"}],"roadmap":[{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/"},{"id":"trial-modernisation-roadmap","kind":"roadmap","name":"Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on","route":"/roadmaps/trial-modernisation-roadmap/"}],"idea":[{"id":"idea-fund-implementation-quota","kind":"idea","name":"A fixed share of trial-group funding for getting proven care to patients","route":"/ideas/idea-fund-implementation-quota/"},{"id":"idea-fund-neutral-platform-sponsor","kind":"idea","name":"A permanent neutral non-profit sponsor for multi-company platform trials","route":"/ideas/idea-fund-neutral-platform-sponsor/"},{"id":"idea-tr2-public-combination-formulary","kind":"idea","name":"A publicly held library of investigational drugs available for academic combination trials","route":"/ideas/idea-tr2-public-combination-formulary/"},{"id":"idea-gbc-randomised-adjuvant-chemoradiation-r1-node-positive","kind":"idea","name":"A randomised trial of adjuvant chemoradiation after margin-positive or node-positive gallbladder cancer resection","route":"/ideas/idea-gbc-randomised-adjuvant-chemoradiation-r1-node-positive/"},{"id":"idea-data-registry-follow-up-of-trial-participants","kind":"idea","name":"Follow every trial participant for 30 years through registry linkage","route":"/ideas/idea-data-registry-follow-up-of-trial-participants/"}],"bottleneck":[{"id":"b-aging-comorbidity","kind":"bottleneck","name":"Older and multimorbid patients are excluded and undertreated","route":"/bottlenecks/b-aging-comorbidity/"},{"id":"b-trial-diversity","kind":"bottleneck","name":"Trials do not represent the people who get cancer","route":"/bottlenecks/b-trial-diversity/"},{"id":"b-trial-enrolment","kind":"bottleneck","name":"Trials enrol too few, too slowly","route":"/bottlenecks/b-trial-enrolment/"}]}}